Human tripeptidyl-peptidase I (TPP I, CLN2 protein) is a lysosomal serine protease that removes tripeptides from the free N termini of small polypeptides and also shows a minor endoprotease activity. Due to various naturally occurring mutations, an inherited deficiency of TPP I activity causes a fatal lysosomal storage disorder, classic late infantile neuronal ceroid lipofuscinosis (CLN2). In the present study, we analyzed biosynthesis, glycosylation, transport, and proteolytic processing of this enzyme in stably transfected Chinese hamster ovary cells as well as maturation of the endocytosed proenzyme in CLN2 lymphoblasts, fibroblasts, and N2a cells. Human TPP I was initially identified as a single precursor polypeptide of ϳ68 kDa, which, within a few hours, was converted to the mature enzyme of ϳ48 kDa. Degradation of polypeptides requires the collective action of various endo-and exopeptidases, finally releasing free amino acids and dipeptides reused in the cell cytoplasm according to the metabolic needs of the cell. Two tripeptidyl peptidases identified to date in mammalian cells sequentially cleave tripeptides from the N termini of oligopeptides: tripeptidyl peptidase I (TPP I, 1 CLN2 protein) and tripeptidyl peptidase II (TPP II) (for a recent review, see Ref.